NCT04817111View on ClinicalTrials.gov

NAD+ Precursor Supplementation in Friedreich's Ataxia

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions
Friedreich Ataxia
Interventions
DRUG

MIB-626

Two (2) 500 mg Tablets, By Mouth, Daily

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

lead

Metro International Biotech, LLC

INDUSTRY